Page last updated: 2024-12-04
beta-amanitin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
beta-amanitin: RN given refers to L-Asp [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 2276 |
CHEMBL ID | 1978871 |
SCHEMBL ID | 3505949 |
MeSH ID | M0141072 |
Synonyms (13)
Synonym |
---|
nsc-627727 |
.beta.-amanitin |
nsc627727 |
NCI60_008881 |
beta-amanitin |
beta-amanitin from amanita phalloides, ~90% (hplc) |
21150-22-1 |
SCHEMBL3505949 |
CHEMBL1978871 |
J-013881 |
IEQCUEXVAPAFMQ-UHFFFAOYSA-N |
2-[34-butan-2-yl-13-(3,4-dihydroxybutan-2-yl)-8,22-dihydroxy-2,5,11,14,27,30,33,36,39-nonaoxo-27lambda4-thia-3,6,12,15,25,29,32,35,38-nonazapentacyclo[14.12.11.06,10.018,26.019,24]nonatriaconta-18(26),19(24),20,22-tetraen-4-yl]acetic acid |
beta -amanitin |
Research Excerpts
Toxicity
Excerpt | Reference | Relevance |
---|---|---|
" Twice as toxic as free alpha-amanitin." | ( Strongly enhanced toxicity of the mushroom toxin alpha-amanitin by an amatoxin-specific Fab or monoclonal antibody. Derenzini, M; Faulstich, H; Kirchner, K, 1988) | 0.27 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (29)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (10.34) | 18.7374 |
1990's | 4 (13.79) | 18.2507 |
2000's | 5 (17.24) | 29.6817 |
2010's | 9 (31.03) | 24.3611 |
2020's | 8 (27.59) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 20.99
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.99) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 2 (6.90%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 27 (93.10%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |